Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]
Discontinued
Reference number: GID-TA10631
Following on from information provided to NICE by the company in May 2020 the appraisal of Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.